Evaluation of ER, PR and HER2 status is necessary to assess tumor biology and to determine the use of hormone therapy (for ER- and/or PR-positive breast cancer) and targeted therapy with trastuzumab (for HER2-positive tumors) [11]. This evidence concerns the gene ERBB2 and breast carcinoma.